Literature DB >> 3107631

The proliferative response of B cell chronic lymphocytic leukemia to interleukin 2: functional characterization of the interleukin 2 membrane receptors.

I Touw, L Dorssers, B Löwenberg.   

Abstract

To determine the growth properties of B cell chronic lymphocytic leukemia (B CLL) and to identify possible abnormalities thereof, we examined the in vitro action of interleukin 2 (IL2) in four patients. Using radiolabeled IL2 and monoclonal antibodies reactive with IL2 membrane receptors we show that CLL cells, after their activation in vitro, express IL2 receptors of a high- as well as a low-affinity type, exactly as has been reported for normal T and B blasts. In three of the four reported cases, CLL proliferation (measured with 3H-thymidine incorporation) depended on the addition of phytohemagglutinin (PHA) to activate the cells and IL2 (optimal concentration, 10 to 100 U IL2/mL). In contrast, the cells of the fourth case of CLL (CLL-4) proliferated in an autonomous fashion, ie, without a need for PHA and IL2 in culture. Specific blocking of the IL2-binding sites with anti-IL2 receptor monoclonal antibodies almost completely inhibited the proliferation of these cells, which indicated that functional IL2 receptors were required for the autonomous proliferation. The demonstration of low concentrations of IL2 activity in the culture medium conditioned by the cells suggests that endogenous IL2 had been responsible for the spontaneous 3H-thymidine uptake by the CLL cells of patient 4. However, we were unable to extract IL2 mRNA from the cells (neither fresh nor after various in vitro incubations) in quantities detectable by Northern blot analysis that would prove that the CLL cells of patient 4 were actively synthesizing IL2 during culture. Thus, individual cases of B CLL are subject to variable growth regulation involving functional IL2 receptors on the cell surface: after activation with PHA the cells respond to exogenous IL2 in a fashion similar to normal B lymphocytes, or the cells are stimulated by endogenous IL2 (or an IL2-like activity) and do not require activation with PHA.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3107631

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  6 in total

1.  A disturbance of the IL-2/IL-2 receptor system parallels the activity of multiple myeloma.

Authors:  A Vacca; R Di Stefano; A Frassanito; G Iodice; F Dammacco
Journal:  Clin Exp Immunol       Date:  1991-06       Impact factor: 4.330

2.  Demonstration of high-affinity interleukin-2 receptors on B-chronic lymphocytic leukemia cells: functional and structural characterization.

Authors:  H Yagura; T Tamaki; T Furitsu; Y Tomiyama; T Nishiura; N Tominaga; S Katagiri; T Yonezawa; S Tarui
Journal:  Blut       Date:  1990-03

3.  Effect of interleukins on the proliferation and survival of B cell chronic lymphocytic leukaemia cells.

Authors:  T Mainou-Fowler; J A Copplestone; A G Prentice
Journal:  J Clin Pathol       Date:  1995-05       Impact factor: 3.411

4.  Serum levels of IL-6 type cytokines and soluble IL-6 receptors in active B-cell chronic lymphocytic leukemia and in cladribine induced remission.

Authors:  T Robak; A Wierzbowska; M Błasińska-Morawiec; A Korycka; J Z Błoński
Journal:  Mediators Inflamm       Date:  1999       Impact factor: 4.711

5.  CD4+ T cells sustain aggressive chronic lymphocytic leukemia in Eμ-TCL1 mice through a CD40L-independent mechanism.

Authors:  Matteo Grioni; Arianna Brevi; Elena Cattaneo; Alessandra Rovida; Jessica Bordini; Maria Teresa Sabrina Bertilaccio; Maurilio Ponzoni; Giulia Casorati; Paolo Dellabona; Paolo Ghia; Matteo Bellone; Arianna Calcinotto
Journal:  Blood Adv       Date:  2021-07-27

6.  Interleukin 4 counteracts the interleukin 2-induced proliferation of monoclonal B cells.

Authors:  S Karray; T DeFrance; H Merle-Béral; J Banchereau; P Debré; P Galanaud
Journal:  J Exp Med       Date:  1988-07-01       Impact factor: 14.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.